Bonness Enterprises Inc. Sells 11,480 Shares of GSK plc (NYSE:GSK)

Bonness Enterprises Inc. lessened its stake in GSK plc (NYSE:GSK) by 21.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,480 shares of the pharmaceutical company’s stock after selling 11,480 shares during the quarter. Bonness Enterprises Inc.’s holdings in GSK were worth $1,403,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. FMR LLC boosted its stake in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Primecap Management Co. CA boosted its position in shares of GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after buying an additional 342,365 shares during the period. Provident Trust Co. grew its holdings in shares of GSK by 1.7% during the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after buying an additional 66,765 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC raised its position in GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK opened at $33.46 on Tuesday. The company has a market cap of $69.34 billion, a PE ratio of 21.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. The firm has a 50-day moving average of $34.02 and a 200-day moving average of $37.97. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were issued a dividend of $0.3928 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a yield of 4.70%. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is presently 96.10%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on GSK. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Seven investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, GSK has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.